Ark Therapeutics Limited

Arktherapeutics Group, Plc

Shire Human Genetic Therapies, Inc.

University of Wales Institute, Cardiff

Finvector Vision Therapies, Ltd.

Jorge Daniel Erusalimsky

John Martin

Hugh Edward Montgomery

Maninder Ahluwalia

John Francis Martin

Methods and kits for identifying candidate anti-megakaryocyte agents are disclosed.

Assays for agents affecting megakaryocyte development

It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

Use of inhibitors of the renin-angiotensin system

Inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia, such as stroke.

It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

An inhibitor of the renin-angiotensin system is useful for the treatment or prevention of the lipodystrophy syndrome, e.g. in AIDS patients also receiving anti-retroviral therapy.

Growing community of inventors

London, United Kingdom

Jorge Daniel Erusalimsky